Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Clinical trial NCT01660906 · COMPLETED
Trial details
- NCT number
- NCT01660906
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2012-12-01
- Primary completion
- 2015-10-01
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.